During the past decade, The Japanese Red Cross Nagasaki Genbaku Hospital conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 6 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 5 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Japanese Red Cross Nagasaki Genbaku Hospital" #1 sponsor was "Celgene" with 8 trials, followed by "Bayer" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Allergan" with 1 trials sponsored and "BeiGene" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Japanese Red Cross Nagasaki Genbaku Hospital" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "The Japanese Red Cross Nagasaki Genbaku Hospital" are "Myelodysplastic Syndromes" (3 trials), "Primary Myelofibrosis" (2 trials), "Adult T-Cell Leukemia-Lymphoma" (1 trials), "Adult T-cell Leukemia-Lymphoma" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "The Japanese Red Cross Nagasaki Genbaku Hospital" in a lesser frequency.

Most popular intervention types in "The Japanese Red Cross Nagasaki Genbaku Hospital" are "Drug" (17 trials), "Other" (3 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Luspatercept" (3 trials), "Sham Procedure" (3 trials), "Faricimab" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Japanese Red Cross Nagasaki Genbaku Hospital" are 17 trials for "All" genders.

Currently, there are NaN active trials in "The Japanese Red Cross Nagasaki Genbaku Hospital". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in The Japanese Red Cross Nagasaki Genbaku Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The Japanese Red Cross Nagasaki Genbaku Hospital, 3 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".